Beta-blocker therapy is not associated with mortality after intracerebral hemorrhage

Acta Neurol Scand. 2018 Jan;137(1):105-108. doi: 10.1111/ane.12817. Epub 2017 Sep 4.

Abstract

Background: Beta-blocker therapy has been suggested to have neuroprotective properties in the setting of acute stroke; however, the evidence is weak and contradictory. We aimed to examine the effects of pre-admission therapy with beta-blockers (BB) on the mortality following spontaneous intracerebral hemorrhage (ICH).

Methods: Retrospective analysis of the Helsinki ICH Study database.

Results: A total of 1013 patients with ICH were included in the analysis. Patients taking BB were significantly older, had a higher premorbid mRS score, had more DNR orders, and more comorbidities as atrial fibrillation, hypertension, diabetes mellitus, ischemic heart disease, and heart failure. After adjustment for age, pre-existing comorbidities, and prior use of antithrombotic and antihypertensive medications, no differences in in-hospital mortality (OR 1.1, 95% CI 0.8-1.7), 12-month mortality (OR 1.3, 95% CI 0.9-1.9), and 3-month mortality (OR 1.2, 95% CI 0.8-1.7) emerged.

Conclusion: Pre-admission use of BB was not associated with mortality after ICH.

Keywords: beta-blockers; intracerebral hemorrhage; mortality; outcome.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Cerebral Hemorrhage / mortality*
  • Comorbidity
  • Female
  • Heart Diseases / drug therapy
  • Heart Diseases / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Young Adult

Substances

  • Adrenergic beta-Antagonists